JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (4): 61-64.doi: 10.6040/j.issn.1671-7554.0.2014.641

Previous Articles     Next Articles

Beta-synuclein promotes the expression of vesicular monoamine transporter-2

YANG Lu1, ZHOU Yingze2, NI Ming1, FAN Xiushuang1, MAN Jianmei1, GUO Juntang1   

  1. 1. Department of Pathophysiology, School of Basic Medicine, Weifang Medical University, Weifang 261053, Shandong, China;
    2. Department of Pathology, Anyue County People's Hospital, Anyue 642350, Sichuan, China
  • Received:2014-09-24 Revised:2014-12-24 Online:2015-04-10 Published:2015-04-10

PDF (PC)

113

Abstract: Objective To investigate the effect of β-synuclein on the expression of vesicular monoamine transporter-2(VMAT2). Methods The effects of β-synuclein stable expression on the intracellular ROS level were detected by dichlorofluorescein diacetata(DCFH-DA). The expression of VMAT2 was detected by double immunofluorescence, immunohistochemistry and Western blotting in SH-SY5Y cells which were transfected stably with β-synuclein and normal SH-SY5Y cells. Results The intracellular ROS level in the cells stably expressing β-synuclein was significantly lower than that of normal SH-SY5Y cells.The expression of β-synuclein in the SH-SY5Y cells which were stably transfected with β-synuclein was higher than that of normal SH-SY5Y cells. Conclusion β-synuclein can reduce the content of DA in cytosolic by promoting the expression of VMAT2, which can inhibit the generation of ROS. It plays an important protective role in the process of dopamine neurons' degeneration in Parkinson's disease.

Key words: Beta-synuclein, Reactive oxygen species, Parkinson's, disease, Vesicular monoamine transporter-2

CLC Number: 

  • R741
[1] Bellucci A, Navarria L, Zaltieri M, et al.Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease[J]. Brain Res, 2012, 1432:95-113.
[2] Ruipérez V, Darios F, Davletov B. Alpha-synuclein, lipids and Parkinson's disease[J]. Prog Lipid Res, 2010, 49(4):420-428.
[3] Lam HA, Wu N, Cely I, et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-Synuclein[J]. Neurosci Res, 2011, 89(7):1091-1102.
[4] Lohr KM, Bernstein AI, Stout KA, et al. Increased vesicular monoamine transporterenhances dopamine release and opposes Parkinson's disease-related neurodegeneration in vivo[J]. Proc Natl Acad Sci U S A, 2014, 111(27):9977-9982.
[5] Brighina L, Riva C, Bertola F, et al.Analysis of vesicular monoamine transporter2 polymorphisms in Parkinson's disease[J]. Neurobiol Aging, 2013, 34(6):1712.e9-13. doi:10.1016/j.neurobiolaging.2012.12.020.
[6] Guo JT, Chen AQ, Kong Q, et al. Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells[J]. Cell Mol Neurobiol, 2008, 28(1):35-47.
[7] Yamin G, Munishkina LA, Karymov MA, et al. Forcing nonamyloidogenic beta-synuclein to fibrillate[J]. Biochemistry, 2005, 44(25):9096-9107.
[8] Cali T, Ottolini D, Negro A, et al. α-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions[J]. Biol Chem, 2012, 287(22):17914-17929.
[9] Nishioka K, Wider C, Vilario-Güell C, et al. Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease[J]. Arch Neurol, 2010, 67(8):970-975.
[10] 沈原,赵永波,刘功禄,等. α-突触核蛋白的表达与氧化应激水平的相互影响[J].中国神经免疫学和神经病学杂志, 2011, 18(3):174-177. SHEN Yuan, ZHAO Yongbo, LIU Gonglu, et al. The interaction between the oxidative stress level and α-synuclein protein expression[J].Chinese Journal of Neuroimmunology and Neurology, 2011, 18(3):174-177.
[11] Okamura N, Villemagne VL, Drago J, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with(18)F-AV-133[J]. Nucl Med, 2010, 51(2):223-228.
[12] Lotharius J, Barg S, Wiekop P, et al. Effect of mutant alpha-synuclein on dopamine-homeostasis in a new human mesencephalic cell line[J]. Biol Chem, 2002, 277(41):38884-38894.
[13] Giasson BI, Murray IV, Trojanowski JQ, et al. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly[J]. Biol Chem, 2001, 276(4):2380-2386.
[14] Tabrizi SJ, Orth M, Wilkinson JM, et al. Expression of mutant alpha- synuclein causes inereased susceptibility to dopamine toxicity[J]. Hum Mol Genet, 2000, 9(18):2683-2689.
[1] XU Ping, YU Guo-Fang, LI Xia. Differential diagnosis of Graves′ disease and Hashimoto′s thyroiditis by different types peak systolic velocity of the superior thyroid artery [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 62-64.
[2] ZHANG Ying, WANG Hong-Wei, WANG Hui, CHEN Fu-Qin. Changes of serum transforming growth factor-β1 level in patients with recurrence of Graves′ disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 80-.
[3] YAN Peng, WANG Rong, DU Yi-Feng, SHEN Lun-Qian. AD7c-NTP level in urine of patients with Alzheimer′s disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 106-.
[4] Xingang LI,Xin ZHANG,Anjing CHEN. The latest advances in human brain projects [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 5-9, 21.
[5] Yilong YIN,Xiaoming XI,Xianjing MENG. Intelligent diagnosis methods of Alzheimer's disease [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 14-21.
[6] Xinguang YU,Yanyang ZHANG. Advances on the treatment of Alzheimer's disease with deep brain stimulation [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 22-27,33.
[7] Chuanzhu YAN,Wei WANG,Kunqian JI,Yuying ZHAO. Mitochondrial dysfunction and related brain diseases [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 34-41.
[8] DENG Qingwen, LIU Wenbin. Multilevel analysis of health related quality of life of patients with cardiovascular disease and its determinants [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 115-121.
[9] LIU Pan, HE Tianyi, ZHAO Ruxing, SUN Yu, CHEN Li. Regulating effect of Bailing capsule on autoimmunity in patients with Graves disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 90-95.
[10] ZHAO Zuohui, LI Cuiling, WANG Daoguang, WANG Fengqin, QU Hongyi, DING Sentai, GONG Jing, LÜ Jiaju, YANG Jinghua. Effect of MnSOD acetylation on the proliferation and apoptosis of clear cell renal cell carcinoma cell line 786-O [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 31-35.
[11] GOU Yun, ZHOU Bo, WEI Cao, CHEN Yunhua, XU Li, LIU Fen, ZHANG Chunlin, WEN Min. Protection of thioctic acid in mitochondria in the rat model of Parkinsons disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(8): 18-23.
[12] CUI Meng, ZHENG Jilu, TIAN Sinan, LI Lianjun, ZHANG Qi, JIN Xunbo, WANG Muwen. Photoselective vaporization of the prostate for the treatment of benign prostatic obstruction in patients with Parkinsons disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 100-102.
[13] ZENG Haiyan, LI Rui, SUN Xindong, XIE Peng, MENG Xue, FAN Bingjie, LI Wanlong, YUAN Shuanghu. Association analysis of brain metastases after prophylactic cranial irradiation in local disease small cell lung cancer: a bicenter study [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 61-66.
[14] XUE Fuzhong. Healthcare big data-driven theory and methodology for health management [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(6): 1-29.
[15] LIU Yafei, XING Ping, XU Xiuqin, YANG Shufang, LIU Yanxun, YUAN Zhongshang, XUE Fuzhong. Shandong multi-center longitudinal cohort for health management: a brief introduction [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(6): 30-36.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd